CRISPR Therapeutics Unveils Promising Data for In Vivo Gene Editing Therapy CTX310 in Severe Hypertriglyceridemia

ZUG, Switzerland and BOSTON – November 09, 2026

CRISPR Therapeutics has revealed promising Phase 1b clinical data for its investigational in vivo gene-editing therapy, CTX310, marking a significant advancement in the treatment of severe hypertriglyceridemia (sHTG). Presented at the American Heart Association (AHA) Scientific Sessions 2026, the data indicates that a single-course treatment with CTX310 can substantially reduce triglycerides and atherogenic lipoproteins, potentially offering a "one-and-done" solution for patients facing this high-risk cardiovascular condition.

This development underscores the company's strategic shift from its foundational success in ex vivo therapies, such as the landmark approval of Casgevy for sickle cell disease, to the broader and more complex landscape of in vivo treatments. By targeting liver-expressed genes, CRISPR Therapeutics aims to address common cardiovascular and metabolic disorders, moving gene editing from niche applications into the mainstream of chronic disease management.

A Potential Paradigm Shift in Lipid Management

The Phase 1b multicenter, open-label trial evaluated CTX310 in a cohort of 10 participants with severe hypertriglyceridemia. These individuals presented with fasting serum triglyceride levels exceeding 500 mg/dL, with a median baseline level surpassing 1,000 mg/dL—a threshold associated with a significantly elevated risk of acute pancreatitis and cardiovascular disease. Furthermore, the patient population was characterized by significant comorbidities: all participants had diabetes, 30% had a history of pancreatitis, and 20% had clinical atherosclerotic cardiovascular disease.

The results at Day 30 following a single intravenous infusion of CTX310 were compelling. The therapy achieved a mean reduction of 65% in circulating angiopoietin-like protein 3 (ANGPTL3) and a 63% reduction in triglycerides. Beyond triglycerides, CTX310 also demonstrated substantial impact on other atherogenic lipoproteins, with mean reductions of 51% in non-high-density lipoprotein cholesterol (non-HDL-C), 23% in apolipoprotein B (ApoB), and a 16% decrease in low-density lipoprotein cholesterol (LDL-C) from a low mean baseline of 60 mg/dL.

Crucially, these reductions were maintained in participants followed for at least 90 days. In a population where 30% had a history of pancreatitis, no events of acute pancreatitis were reported during the study period. This sustained efficacy highlights the potential of CTX310 to not only manage but possibly eliminate the recurrent, life-threatening episodes of acute pancreatitis that plague patients with severe hypertriglyceridemia.

Safety Profile and the In Vivo Frontier

The transition to in vivo gene editing, where the CRISPR/Cas9 machinery is delivered directly into the patient's body, carries inherent safety considerations, particularly concerning immunogenicity, off-target genomic cuts, and hepatic tolerability. The Phase 1b data for CTX310 offers reassuring signs regarding these concerns.

The single-course treatment was reported to be well tolerated among the 10 participants. As of the data cutoff, seven participants had been followed for at least 90 days. The trial recorded no serious adverse events related to CTX310 and no clinically relevant elevations in liver transaminases (AST or ALT). One participant experienced a Grade 2 infusion-related reaction, which resolved, allowing the completion of the infusion. Importantly, there were no Grade 3 or higher adverse events related to the therapy.

These safety findings are critical for the viability of in vivo CRISPR therapies. While the long-term safety profile will require continued monitoring, the absence of significant liver toxicity or severe adverse events in this initial cohort supports the feasibility of systemic lipid nanoparticle (LNP) delivery for gene editing in the liver.

The Competitive Landscape of Lipid-Lowering Therapies

CTX310 enters a dynamic and increasingly crowded field of therapies targeting ANGPTL3 and APOC3, genes known to play pivotal roles in lipid metabolism. The current landscape includes monoclonal antibodies, RNA interference (RNAi) therapies, and antisense oligonucleotides (ASOs), each offering different mechanisms and dosing regimens.

For instance, evinacumab, a monoclonal antibody, has shown substantial triglyceride reductions in patients with severe hypertriglyceridemia but requires intravenous administration every four weeks or subcutaneous injections weekly or bi-weekly. Similarly, RNAi therapies like zodasiran and ASOs like olezarsen have demonstrated significant reductions in triglycerides and target proteins, but they also necessitate chronic administration, typically monthly or quarterly.

The key differentiator for CTX310 lies in its "one-and-done" approach. By permanently disrupting the ANGPTL3 gene in the liver, CTX310 mimics natural loss-of-function mutations associated with reduced cardiovascular risk, potentially eliminating the need for lifelong adherence to chronic medications. This permanent alteration presents both a significant advantage in patient convenience and a unique set of long-term safety considerations compared to reversible modalities.

Another emerging competitor in the gene-editing space is Verve Therapeutics' VERVE-201, which utilizes base editing to introduce a premature stop codon in ANGPTL3 without creating double-strand DNA breaks. As these technologies advance, the comparative efficacy, safety, and durability of different gene-editing approaches will be closely scrutinized.

Regulatory Pathways and Commercial Implications

The U.S. Food and Drug Administration (FDA) has already granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for the treatment of severe hypertriglyceridemia and elevated LDL-C. This designation is designed to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, signaling the FDA's recognition of CTX310's potential to address unmet medical needs.

The RMAT designation could streamline CTX310's path to registrational Phase 2/3 trials, potentially accelerating its time to market. However, the commercialization of a one-time cardiovascular gene therapy presents unique challenges. Pricing models for such therapies must account for the long-term value they provide by potentially eliminating the need for chronic treatments and reducing hospitalizations for acute events like pancreatitis.

As CRISPR Therapeutics continues to advance CTX310 across multiple lipid disorders with ongoing Phase 1b cohorts, the industry will be watching closely. The success of this program could not only transform the management of severe hypertriglyceridemia but also validate the broader application of in vivo CRISPR gene editing for common, chronic diseases, reshaping the future of cardiovascular medicine.